Ascendis Pharma A/S (NASDAQ:ASND) Rating Reiterated by Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating)‘s stock had its “overweight” rating restated by analysts at Cantor Fitzgerald in a note issued to investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Ascendis Pharma A/S’s FY2022 earnings at ($9.07) EPS and FY2023 earnings at ($10.94) EPS.

Several other research firms also recently weighed in on ASND. SVB Leerink dropped their target price on shares of Ascendis Pharma A/S from $174.00 to $168.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. Morgan Stanley lowered their price objective on shares of Ascendis Pharma A/S from $152.00 to $148.00 and set an “overweight” rating on the stock in a research report on Thursday, August 11th. Oppenheimer lowered their price objective on shares of Ascendis Pharma A/S from $154.00 to $144.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. Wells Fargo & Company boosted their price objective on shares of Ascendis Pharma A/S from $167.00 to $172.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Berenberg Bank reaffirmed a “buy” rating and set a $166.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, August 30th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and an average target price of $153.70.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $103.88 on Wednesday. The firm’s 50 day moving average is $94.55 and its 200-day moving average is $96.67. The stock has a market capitalization of $5.92 billion, a P/E ratio of -13.17 and a beta of 0.66. The company has a debt-to-equity ratio of 0.82, a current ratio of 9.66 and a quick ratio of 8.78. Ascendis Pharma A/S has a 12-month low of $61.58 and a 12-month high of $172.65.

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) last released its earnings results on Wednesday, August 10th. The biotechnology company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($2.11) by $0.57. The business had revenue of $6.51 million for the quarter, compared to the consensus estimate of $7.07 million. Ascendis Pharma A/S had a negative net margin of 2,099.51% and a negative return on equity of 48.92%. Equities research analysts anticipate that Ascendis Pharma A/S will post -8.69 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently modified their holdings of ASND. BNP Paribas Arbitrage SA acquired a new stake in shares of Ascendis Pharma A/S in the second quarter worth $67,000. US Bancorp DE lifted its stake in shares of Ascendis Pharma A/S by 58.2% in the second quarter. US Bancorp DE now owns 970 shares of the biotechnology company’s stock worth $90,000 after buying an additional 357 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Ascendis Pharma A/S by 17.8% in the first quarter. SG Americas Securities LLC now owns 942 shares of the biotechnology company’s stock worth $111,000 after buying an additional 142 shares during the last quarter. Captrust Financial Advisors lifted its stake in shares of Ascendis Pharma A/S by 3,069.7% in the first quarter. Captrust Financial Advisors now owns 1,046 shares of the biotechnology company’s stock worth $123,000 after buying an additional 1,013 shares during the last quarter. Finally, Tobam increased its position in Ascendis Pharma A/S by 550.7% during the second quarter. Tobam now owns 1,438 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 1,217 shares during the period.

About Ascendis Pharma A/S

(Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

See Also

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.